Three-gene signature predictive of high residual risk of recurrence after adjuvant chemotherapy in ER-positive HER2-negative breast cancer

被引：0
|
作者：
Gyorffy, B.
Ocana, A.
Herman, P.
Hatzis, C.
Pandiella, A.
Pusztai, L.
机构：
[1] Yale Univ, New Haven, CT 06520 USA
[2] Servicoio Salud Castilla la Mancha, Albacete, Spain
[3] MTA TTK, Budapest, Hungary
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P6-09-49
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-09-49
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Real world outcomes of neoadjuvant chemotherapy in ER-positive/PR-positive, HER2-negative breast cancer
    Kurian, Matthew
    Trybula, Marcus
    Patell, Kanchi
    Guzik, Gregory
    Margevicius, Seunghee
    Fu, Pingfu
    Montero, Alberto
    Martin, James
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer
    Hamilton, Erika P.
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (03) : 125 - 127
  • [23] The impact of intratumoral heterogeneity on the prognosis of ER-positive/HER2-negative breast cancer
    Oikawa, Masahiro
    Ishida, Mayumi
    Nakamura, Yoshiaki
    Nishimura, Sumiko
    Koga, Chinami
    Saruwatari, Akihiro
    Igawa, Akiko
    Akiyoshi, Sayuri
    Koi, Yumiko
    Ohno, Shinji
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    L S Rigter
    C E Loo
    S C Linn
    G S Sonke
    E van Werkhoven
    E H Lips
    H A Warnars
    P K Doll
    A Bruining
    I A Mandjes
    M J Vrancken Peeters
    J Wesseling
    K G Gilhuijs
    S Rodenhuis
    British Journal of Cancer, 2013, 109 : 2965 - 2972
  • [25] High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
    Voutsadakis, Ioannis A.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
  • [26] The EndoPredict Score Is a Response Predictor for Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer.
    Brase, J. C.
    Gehrmann, M. C.
    Petry, C.
    Weber, K. E.
    Schmidt, M.
    Koelbl, H.
    Brauch, H.
    Schwab, M.
    Mueller, V.
    Jaenicke, F.
    Rody, A.
    Kaufmann, M.
    Filipits, M.
    Gnant, M.
    Denkert, C.
    Loibl, S.
    von Minckwitz, G.
    Kronenwett, R.
    CANCER RESEARCH, 2011, 71
  • [27] Estimating the magnitude of clinical benefit of chemotherapy in patients with early ER-positive, HER2-negative breast cancer
    McCartney, A.
    Di Leo, A.
    BREAST, 2019, 44 : S11 - S11
  • [28] Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
    Rigter, L. S.
    Loo, C. E.
    Linn, S. C.
    Sonke, G. S.
    van Werkhoven, E.
    Lips, E. H.
    Warnars, H. A.
    Doll, P. K.
    Bruining, A.
    Mandjes, I. A.
    Peeters, M. J. Vrancken
    Wesseling, J.
    Gilhuijs, K. G.
    Rodenhuis, S.
    BRITISH JOURNAL OF CANCER, 2013, 109 (12) : 2965 - 2972
  • [29] Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
    Hoste, G.
    Punie, K.
    Wildiers, H.
    Beuselinck, B.
    Lefever, I.
    Van Nieuwenhuysen, E.
    Han, S. N.
    Berteloot, P.
    Concin, N.
    Salihi, R.
    Vergote, I.
    Neven, P.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 171 (01) : 131 - 141
  • [30] Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer
    Matikas, Alexios
    Foukakis, Theodoros
    Michalakis, Ilias
    Georgoulias, Vassilis
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) : 319 - 326
12345